CartilaGen

CartilaGen is a biotechnology company focused on developing CG-001, an intra-articular injection designed to prevent post-traumatic osteoarthritis (PTOA) following traumatic joint injuries like ankle fractures. The therapy utilizes a small-molecule drug, amobarbital, to act as a reversible inhibitor of Complex I in the mitochondrial electron transport chain. By reducing the surge of reactive oxidant species immediately after injury, the treatment aims to protect chondrocytes and maintain cartilage structure, addressing the underlying disease mechanism rather than just managing symptoms. The company's approach is designed for simple administration during standard orthopedic surgical procedures, such as Open Reduction and Internal Fixation, to integrate seamlessly into existing clinical workflows.

This novel therapeutic is aimed at patients at high risk for PTOA, a debilitating condition that often leads to significant disability and long-term joint degeneration. CartilaGen’s development efforts are supported by large-animal preclinical studies showing sustained protective effects, and the company has secured Department of Defense funding to advance its clinical trials. By providing a disease-modifying option in a field previously lacking effective preventative therapies, CartilaGen seeks to improve patient outcomes and quality of life while reducing the long-term healthcare burdens associated with joint trauma. The company has engaged with recognized clinical research leaders and institutional partners to validate its technology and move toward regulatory milestones.